These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1662327)

  • 1. Mineralocorticoid receptor ligands: biochemical, pharmacological, and clinical aspects.
    Sutanto W; de Kloet ER
    Med Res Rev; 1991 Nov; 11(6):617-39. PubMed ID: 1662327
    [No Abstract]   [Full Text] [Related]  

  • 2. Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation.
    Schiffer L; Müller AR; Hobler A; Brixius-Anderko S; Zapp J; Hannemann F; Bernhardt R
    J Steroid Biochem Mol Biol; 2016 Oct; 163():68-76. PubMed ID: 27125452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimineralocorticoids.
    Agarwal MK; Lazar G
    Ren Physiol Biochem; 1991; 14(6):217-23. PubMed ID: 1720252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical pharmacology. Pharmacokinetics and affinity of drugs for their receptors, Apropos of anti-aldosterone].
    Thebault JJ; Duchier J; Corvol P
    Sem Hop Ther; 1976; 52(7-8):403-6. PubMed ID: 996562
    [No Abstract]   [Full Text] [Related]  

  • 5. Paradoxical differences in the receptor binding of two new antimineralocorticoids.
    Agarwal MK; Kalimi M
    Biochim Biophys Acta; 1988 Jan; 964(1):105-12. PubMed ID: 2825817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of the antimineralocorticoid effects of spirolactones.
    Corvol P; Claire M; Oblin ME; Geering K; Rossier B
    Kidney Int; 1981 Jul; 20(1):1-6. PubMed ID: 7029118
    [No Abstract]   [Full Text] [Related]  

  • 7. A Mixed Glucocorticoid/Mineralocorticoid Selective Modulator With Dominant Antagonism in the Male Rat Brain.
    Atucha E; Zalachoras I; van den Heuvel JK; van Weert LT; Melchers D; Mol IM; Belanoff JK; Houtman R; Hunt H; Roozendaal B; Meijer OC
    Endocrinology; 2015 Nov; 156(11):4105-14. PubMed ID: 26305887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacology profile and clinical findings of Selara Tablets (eplerenone)].
    Nomura S; Tabira J; Hayashi T; Hamada Y
    Nihon Yakurigaku Zasshi; 2008 Oct; 132(4):227-35. PubMed ID: 18854625
    [No Abstract]   [Full Text] [Related]  

  • 9. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential.
    Fuhrmann U; Krattenmacher R; Slater EP; Fritzemeier KH
    Contraception; 1996 Oct; 54(4):243-51. PubMed ID: 8922878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Properties and distribution of binding sites for the mineralocorticoid receptor antagonist [3H]ZK 91587 in brain.
    Grillo C; Vallee S; McEwen BS; De Nicola AF
    J Steroid Biochem; 1990 Jan; 35(1):11-5. PubMed ID: 2155344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative dose-effect studies with four C-17-spirosteroidal mineralocorticoid synthesis inhibitors.
    Weindel K; Lewicka S; Vecsei P
    J Steroid Biochem; 1989; 34(1-6):455-9. PubMed ID: 2626039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the role of brain mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation.
    Ratka A; Sutanto W; Bloemers M; de Kloet ER
    Neuroendocrinology; 1989 Aug; 50(2):117-23. PubMed ID: 2550833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of mineralocorticoid receptor function in treatment-resistant depression.
    Juruena MF; Pariante CM; Papadopoulos AS; Poon L; Lightman S; Cleare AJ
    J Psychopharmacol; 2013 Dec; 27(12):1169-79. PubMed ID: 23904409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A structure-activity relationship study of spirolactones. Contribution of the cyclopropane ring to antimineralocorticoid activity.
    Chinn LJ; Salamon KW; Desai BN
    J Med Chem; 1981 Sep; 24(9):1103-7. PubMed ID: 6270335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of pharmacological mineralocorticoid and glucocorticoid receptor blockade on the cortisol response to psychological stress.
    Deuter CE; Kaczmarczyk M; Hellmann-Regen J; Kuehl LK; Wingenfeld K; Otte C
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Feb; 129():110905. PubMed ID: 38043634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of mineralocorticoid agonist and antagonist specific receptors from rat kidney.
    Agarwal MK; Kalimi M
    Biochem Biophys Res Commun; 1987 Feb; 143(1):398-402. PubMed ID: 3030321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mifepristone protects CA1 hippocampal neurons following traumatic brain injury in rat.
    McCullers DL; Sullivan PG; Scheff SW; Herman JP
    Neuroscience; 2002; 109(2):219-30. PubMed ID: 11801359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationships for agonistic and antagonistic mineralocorticoids.
    Genard P; Palem-Vliers P
    J Steroid Biochem; 1980 Nov; 13(11):1299-305. PubMed ID: 6256585
    [No Abstract]   [Full Text] [Related]  

  • 19. Aldosterone antagonists destabilize the mineralocorticosteroid receptor.
    Couette B; Lombes M; Baulieu EE; Rafestin-Oblin ME
    Biochem J; 1992 Mar; 282 ( Pt 3)(Pt 3):697-702. PubMed ID: 1313229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding of corticosteroid receptors to rat hippocampus nuclear matrix.
    van Steensel B; van Haarst AD; de Kloet ER; van Driel R
    FEBS Lett; 1991 Nov; 292(1-2):229-31. PubMed ID: 1659997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.